EUVIMEDEUVIMED entdecken
Open Access

Targeting miR-21 to Overcome P-glycoprotein Drug Efflux in Doxorubicin-Resistant 4T1 Breast Cancer

Eun Hye Kim, Youngri Ryu, Jiwoong Choi, Daeho Park, Jong Won Lee, Sung-Gil Chi, Sun Hwa Kim, Yoosoo Yang iD

Biomaterials Research · 2024-01 · 28

DOI: 10.34133/bmr.0095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomaterials Research, online erschienen am 21.10.2024. Verfasst von Eun Hye Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Materials Research Center, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Research Foundation, KU-KIST.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acquired resistance to chemotherapy is a major challenge in the treatment of triple-negative breast cancer (TNBC). Despite accumulated evidence showing microRNA-21 (miR-21) as a vital regulator of tumor progression, the role of miR-21 in modulating the multidrug resistance of TNBC remains obscure. In this study, we demonstrate that miR-21 affects chemoresistance in 4T1 TNBC cells in response to doxorubicin (DOX) by regulating the P-glycoprotein (P-gp) drug efflux pump. Overexpression of miR-21 in the 4T1 cells markedly reduced their sensitivity to DOX, impeding DOX-promoted cell death. We employed anti-miR-21 oligonucleotide conjugated with a PD-L1-binding peptide (P21) for targeted delivery to 4T1 tumor cells. The selective down-regulation of miR-21 in 4T1 TNBC led to the reversal of P-gp-mediated DOX resistance by up-regulating phosphatase and tensin homolog (PTEN). Our study highlights that miR-21 is a key regulator of drug efflux pumps in TNBC, and targeting miR-21 could enhance DOX sensitivity, offering a potential therapeutic option for patients with DOX-resistant TNBC.

Autor:innen und Institutionen

  • Medicinal Materials Research Center, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea.
  • Department of Life Sciences, Korea University, Seoul 02841, Republic of Korea.
  • KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Republic of Korea.
  • Division of Bio-Medical Science and Technology, KIST School, University of Science and Technology, Seoul 02792, Republic of Korea.

ORCID-Profile: Yoosoo Yang

Förderung

  • National Research Foundation
  • KU-KIST

Zitieren

APA

Kim, E. H., Ryu, Y., Choi, J., Park, D., Lee, J. W., Chi, S. G., Kim, S. H., & Yang, Y. (2024). Targeting miR-21 to Overcome P-glycoprotein Drug Efflux in Doxorubicin-Resistant 4T1 Breast Cancer. Biomaterials Research, 28. https://doi.org/10.34133/bmr.0095

Vancouver

Kim EH, Ryu Y, Choi J, Park D, Lee JW, Chi SG, et al. Targeting miR-21 to Overcome P-glycoprotein Drug Efflux in Doxorubicin-Resistant 4T1 Breast Cancer. Biomaterials Research. 2024;28. doi:10.34133/bmr.0095

BibTeX
@article{Kim2024,
  author = {Kim, Eun Hye and Ryu, Youngri and Choi, Jiwoong and Park, Daeho and Lee, Jong Won and Chi, Sung-Gil and Kim, Sun Hwa and Yang, Yoosoo},
  title = {Targeting miR-21 to Overcome P-glycoprotein Drug Efflux in Doxorubicin-Resistant 4T1 Breast Cancer},
  journal = {Biomaterials Research},
  year = {2024},
  volume = {28},
  doi = {10.34133/bmr.0095}
}
Kostenlos starten →